Table 1.
Characteristics of clinical isolates used in this study
| Bacterial species | Clinical isolates | # of patients | Pulsed- Field Type (PFTs) | *Phenotype | Site of isolation |
|---|---|---|---|---|---|
|
E. coli |
39 |
32 |
1 (n=4) |
ESBL+ (n=31) |
Wound culture (n=10) |
| |
|
|
2 (n=5) |
|
Blood (n=4) |
| |
|
|
3 (n=3) |
|
Urine (n=21) |
| |
|
|
4 (n=7) |
|
|
| |
|
|
7 (n=5) |
|
|
| |
|
|
Other (n=15) |
|
|
|
K. pneumoniae |
54 |
33 |
1 (n=6) |
MDR (n=54) |
Wound culture (n=39) |
| |
|
|
2 (n=8) |
|
Blood (n=10) |
| |
|
|
3,4,14,16,17, 18 (n=5) |
|
Respiratory (n=5) |
| |
|
|
Other (n=10) |
|
|
|
P. aeruginosa |
36 |
17 |
1 (n=7) |
MDR (n=28) |
Wound culture (n=29) |
| |
|
|
2, 18 (n=5) |
|
Blood (n=7) |
| |
|
|
Other (n=19) |
|
|
|
A. baumannii |
53 |
47 |
1 (n=13) |
MDR (n=46) |
Wound culture (n=31) |
| |
|
|
5 (n=4) |
|
Blood (n=20) |
| 2,3,4, 6,7,14 (n=5) |
|
Urine (n=1) |
|||
| |
|
|
Other (n=6) |
|
Respiratory (n=1) |
|
S. aureus |
23 |
21 |
USA100 (n=10) |
MRSA (n=15) |
Wound culture (n=14) |
| |
|
|
USA200, USA800 (n=4) |
MSSA (n=8) |
Blood (n=4) |
| |
|
|
USA300 (n=2) |
|
Respiratory (n=5) |
| USA700 (n=3) |
*A multidrug-resistant (MDR) organism was defined as any extended spectrum beta-lactamase (ESBL)-producing bacteria, or if resistant to all tested antimicrobials in 3 or more classes of antimicrobial agents (penicillins/cephalosporins, carbapenems, aminoglycosides, and quinolones) not including tetracyclines or colistin.